This site is updated Hourly Every Day

Trending Featured Popular Today, Right Now

Colorado's Only Reliable Source for Daily News @ Marijuana, Psychedelics & more...

Post: US FDA panel to discuss first psychedelic-assisted PTSD treatment next month

Picture of Anschutz Medical Campus

Anschutz Medical Campus

AnschutzMedicalCampus.com is an independent website not associated or affiliated with CU Anschutz Medical Campus, CU, or Fitzsimons innovation campus.

Categories

Recent Posts

Anschutz Medical Campus

US FDA panel to discuss first psychedelic-assisted PTSD treatment next month
Facebook
X
LinkedIn
WhatsApp
Telegram
Threads
Email

May 6 (Reuters) – The U.S. FDA’s panel of independent advisers will on June 4 deliberate whether they should recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder, Lykos Therapeutics said on Monday.

This would be the first FDA panel of outside experts to review a potential new PTSD treatment in 25 years.

PTSD is a disorder caused by very stressful events and can significantly disrupt patients’ lives.

Decades of studies has shown that psychoactive ingredients, whether derived from cannabis, LSD or magic mushrooms, have long captivated mental health researchers in their quest for treatments.

In support of its application, Lykos Therapeutics, formerly known as Multidisciplinary Association for Psychedelic Studies (MAPS), studied the party drug MDMA, more commonly called ecstacy or molly, in two late-stage studies.

The drug is intended to be used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider. New Tab Reporting by Pratik Jain in Bengaluru; Editing by Krishna Chandra Eluri New Tab

Leave a Reply

Your email address will not be published. Required fields are marked *

You Might Be Interested...